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maturation was accelerated In the ISS and GHD groups. 
HSDS for bone age and predicted adult height did not 
change In either group. Final height In 12 children of the 
ISS group was -  2-6 ±  1 *0 SDS. In the untreated controls 
final height was similar. A low Integrated GH concentra­
tion over 24 hours, a low GH peak to provocative stimuli, 
and minimal Initial BA delay predicted a favourable 
outcome.
CONCLUSION rhGH treatment In this group of children 
with idiopathic short stature did not increase average 
final height. Part of the heterogeneity of the response can 
be attributed to the variation in endogenous GH secretion 
and initial bone age delay.
Summary
BACKGROUND AND OBJECTIVE Growth hormone treat­
ment in children with idiopathic short stature (ISS) leads 
to growth acceleration in the first years, but the effect on 
final height Is still poorly documented. We therefore 
studied the long-term effect of GH therapy in children 
with Idiopathic short stature.
DESIGN We have treated 27 prepubertal children with ISS 
with recombinant human GH (rhGH) in an Initial dosage of 
2 IU/m2 body surface/day subcutaneously, which was 
doubled either after the first year if the height velocity 
increment was less than 2 cm/year, or thereafter if height 
velocity fell below the P50 for bone age. Growth and bone 
maturation of the treatment group (ISS group, n =  21) 
were compared to those of an untreated control group 
with ISS (ISS controls, n — 27) and of a group of rhGH 
treated children with isolated GH deficiency (GHD group, 
^  f
r e s u l t s  In 9 patients of the ISS group still on treatment, 
height standard deviation score (HSDS) for chronological 
age Increased from — 3*8 ±  0-7 to —2*3 ±  0*9 (mean ±  
standard deviation) over 6 years, while In matched ISS 
controls HSDS for age did not change. HSDS for age in the 
GHD group Increased from — 3'9 ±  0-6 to —1 "8 ±  0’7 after 4 
years, significantly more than the ISS group. Bone
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It has been suggested that some children with idiopathic 
short stature (ISS), including familial short stature and/or 
constitutional delay, may have a low spontaneous GH 
secretion in contrast to normal serum GH responses to 
provocative testing, a condition called ‘GH neurosecretory
dysfunction’ (Bereu et al„ ; Spiliotis et al., 1984).
Although this term cannot be clearly defined, even less 
adequately than the term GH deficiency (GHD), GH 
secretion certainly varies among the children with ISS and 
it is suggested that some of these children may produce less
GH they for adequate growth (Albertsson
Wikland & Rosberg, 1988; Zadik et a!., 1992a). Theoreti­
cally, such children would increase their growth rate on a 
regular substitution dosage of GH, while children with an 
adequate GH secretion and a relative GH insensitivity 
would need a higher dosage to grow Taster. This hypothesis 
is supported by the observation that GH treatment in 
various dosages leads to a significant acceleration of the 
average height velocity during the first years of treatment, 
though with a considerable inter-individual variation 
(Hopwood et at., 1993; Hindmarsh & Brook, 1987; Moore 
et al., 1992).
In previous studies we have shown that GH therapy in a 
regular substitution dosage leads to evident catch up growth
(Wit 1989b) and that
doubling the dosage in the poor responders causes a similar
(Wit et al., 1989a; 1990). We
term on statural growth, bone
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maturation, pubertal development and final height in these 
children. We tested the hypothesis that GH leads to a 
significant growth response in comparison to untreated 
controls, but that this response is less than that observed in 
children with ‘classic’ isolated GH deficiency. We further 
evaluated the predictive value of clinical and biochemical 
variables for the effect of GH therapy on final height.
Methods
Patient population
Thirty prepubertal children (21 boys and 9 girls) with ISS 
were selected from five Dutch paediatric endocrine centres. 
To participate in this study the children had to fulfil the 
following criteria: age above 6 years, bone age according to 
Tanner and Whitehouse method II (20 bones) less than 10 
years in girls or 11 years in boys, HSDS for age less than 
—2-5 compared to Dutch cross-sectional standards (Roede
& Van Wieringen, 1985), height velocity for bone age below 
the 25th percentile (Tanner et al., 1966) and plasma GH 
levels >7-5 /xg/1 (15mU/l) in at least one standard provoca­
tion test. Organic causes of growth failure were excluded. 
The study was approved by the hospital ethical committees 
of the participating centres and informed consent was 
obtained from all parents and patients.
Initially the children were randomly assigned to a 
treatment group or to a prospective control group. During 
the first year of the study, a significant increase in height 
velocity occurred in the treatment group (Wit et al., 1989b), 
and subsequently therapy was also offered to the control 
group for ethical reasons. Three children decided to remain 
without rhGH therapy, one of whom later participated in
another study, resulting in a treatment group of 27 children. 
During the follow-up period, 6 of these 27 patients dropped 
out of the study. One child stopped after 6 months because 
she had a poor growth response in the presence of a high 
titre of antibodies; the remaining five children stopped 
therapy after 9 months and 1,2 ,3 , and 4 years of treatment 
due to poor compliance. The patients who dropped out of 
the study did not differ from the patients who remained on 
therapy regarding age, HSDS for age or bone age at the start 
of therapy, or for response to rhGH therapy in terms of 
height velocity and the change in HSDS for age. Hence, the 
final number of children who received long-term rhGH was 
reduced to 21 (14 boys, 7 girls). Four of these children were 
classified (Ranke, 1991) as familial short stature, 5 as 
constitutional delay, 6 as a combination of both, 4 (one of 
whom had stigmata suggestive of Silver-Russell syndrome) 
as persistent short stature after intrauterine growth 
retardation and 2 as unspecified ISS. At present, 9 of these 
children are still undergoing treatment (ISS group 1, n =  9,
7 boys), whereas 12 children have reached final height 
(ISS-group 2, n — 12, 7 boys). Relevant data on these 
groups, as well as on control groups which are described 
below, are shown in Tables 1 and 2.
Control groups
As the original prospective control group was reduced to 2 
children, we retrospectively collected growth data for 
untreated children with ISS. From the medical records of 
all Dutch paediatric endocrinology centres, 27 children were 
recruited who fulfilled the same inclusion criteria as the 
study group and for whom individual growth data over 
6 years as well as data on final height could be obtained
Table 1 Data before and during GH treatment of ISS patients still on GH therapy in comparison with matched controls and GHD patients
(N (Male/female))
Duration of GH-trcatment Start
• »  *  i — ,  > ;* •  * *  -  .  ...................................* b> . . .  -, '
ISS Group 1 (9(7/2))
■ 1 1 1 1 1  ■ ■  "  ,  .  > 3 » ^  . .  +  1 h  U I  ì  ■  ‘ 1 i t ì i ì . T f a i  ---------------- & ----------------
4 years GH 6 years GH
Matched ISS controls (9(7/2))
.  »  I i f - ,  — .  • 1 »  / . n . a  ^  . a  v_-_- I I I .  4 1 -  Jm 1 4 ,  <1 «•< *, —  n l -----■ V* <
Start 4 years GH 6 years GH
GHD Group (7(3/4)) 
Start 4 years GH
Age (years) 9-2± 1 ’6 13-2 ± 1 *5 15’2± 1 -6 9*1 ±1*7 13*1 ±  1*7 15-1 ±1*7 8-2±2-0 12-2 ±2-0
Height (cm) 115-6±8-9 141-5 ± 7 ’6 152-3± 101 118*4±8*7 134*2±8*1 145*1 ±8<8 110-2±9-5 140-9 ±11-2
Height (SDS for age) -3-8±0-7 -2-5 ±0-7** —2-3dr 0-9** -3*2 ±0*3 -3*4±0-6 -3*3 ±0*6 “ 3'9d:0‘6 — 1-8 dbO'7*
Bone age (G-P)f 6-4± 1*6 11-8 ±1-0 13’4±  0-9 n.a. n.a. n.a. 5-8±2-l 10-8 db20
Height (SDS for BA-G-P)t _  i .o± i-7 — 1 *5 ±  M — 1 • 1 dr 1-2 n.a. n.a. n.a. — 1 • 1 dr 1 ‘3 -0'9:fc0'6
Prediction (SDS)t,$ —2-4Ì1-7 —2-l db 1 *2 — 1 -8rb 1 6 n.a. n.a. n.a, n.a.§ — 1 '7 rfcO'7
t n =  6 in the GHD group because the bone age after 4 years of GH therapy is missing in l patient,
i  n =  8 in the ISS group because the bone age at start was too low for prediction in l case.
§ Not available; in 5 cases the bone age at start was too low for prediction.
* P < 005 compared to start.
** P < 0-01 compared to start, 
n.a., Not available.
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Table 2 Data of patients who reached final height.
ISS Group 2 ISS controls ISS BA controls
N (Male/female)
Start 
Age (years)
Bone age (G-P)
Height (cm)
Height (SDS for age)
Height (SDS for bone age G-P) 
Prediction (cm)
Prediction (SDS)
Final measurement 
Age (year)
Height (cm)
Height (SDS for age)
Height (SDS for adults) 
Height-prediction at 0 (cm) 
Height—target height (cm)
12 (7/5)
11 -2± 1-5 
8-4±l-3 
124-6±7-9 
—3 '5 ±0-8 
— 1 '5 dh0‘6 
158*8 rix7*9 
—2*7 ±0-6
16-9db 1 -3 
I59-2±8'0 
—2-4Ì0-9 
- 2 - 6  ± 1 -0  
0-4±5-0 
-8-7±6-5
riTMrtu •■m-irj-rvL. I — .i-f-Trmtlifi iHf.Tt r - j :J-  —  --r................................................... .■¿■„wy#- ..... .....
27 (16/11)
10-5 ±  1 '2
n.a.
125-5 ±  5'4 
™3"0 dt: 0*4 
n.a. 
n.a. 
n.a.
22-0±3-I 
160-6 ±6-6  
“ 2-4 ±0-7  
-2 -4  ±0-7
n.a.
—8'9 ±4-9
9(5/4)
KM rtO-9 
7-6 i 1 -4 
123-4 ±4-5 
“3‘1 ±0-3 
0-8 ±  1 -4 
160-2 ±6-7* 
2-4 tQ'7*
22-3 ±2-6 
159-0 16-9 
..2-6 1 0-9
2-6 dfc 0-9 
2-0 ±3-5* 
1Q'2± 3-5
T
* n =  7, for two patients the bone age at start was too low for prediction 
n.a., Not available.
(ISS controls). Four of these patients were classified (Ranke, 
1991) as familial short stature, 18 as constitutional delay and 
5 as a combination of both. They had not undergone any 
treatment known to influence adult height. The ‘start’ of the 
observation period for these children was defined as the visit 
to the hospital when they had an age close to the mean age at 
start of the study population. In 9 subjects it was possible to 
have a reassessment by the principal investigator (JMW) of 
an X-ray of the left hand made at the start of the observation 
period.
A second group used for the analysis was formed by 
patients with isolated GHD who were selected retrospec­
tively from the Dutch nationwide database on GH treated
individuals. The GHD had to fulfil ì same
inclusion criteria as the study group with exception of the 
maximum plasma GH level, which had to be below 7-5 /¿g/1 
in all performed standard provocation tests. Moreover, GH 
therapy had to be administered at a frequency of 6 or 7 
injections/week and a minimum of 4 years of follow-up after 
start of GH treatment had to be available. Of the 89 patients 
with isolated GHD in the database only 7 patients fulfilled 
all requirements (GHD group, n =  7). The GH dosage used 
in the GHD-group over 4 years was 14-8 ±  4-1 IU/m2/week 
(mean ±  SD).
Treatment protocol
During the first 2 years of the study treatment consisted of 
biosynthetic methionyl human GH (Somatonorm, Kabi
Pharmacia, Sweden) and from the third year onwards this 
was replaced by authentic recombinant human GH 
(Genotropin, Pharmacia). In all ISS patients treated with 
rhGH the starting dosage was 2 IU/m2 body surfacc/day 
administered 7 times a week subcutaneously. The individual 
results of therapy were evaluated yearly and children were 
categorized as responders or non-responders. After the first 
year of the study a non-responder was defined by a height 
velocity increment of less than 2 cm/year. From the second 
year onwards a child was labelled as a non-responder if 
the height velocity dropped below the 50th percentile for 
bone age. In the non-responders, the dosage was doubled to
4 IU/m2 body surface daily.
Evaluation
At baseline, a 24-hour serum GH profile and the plasma 
IGF-I concentration was determined in the initial treatment
was obtained by a Cormcdgroup. The GH
automatic exfusion pump with 20 minutes sampling 
the integrated concentration of serum GH was calculated. 
The assays of serum GH and plasma IGF-I have been 
described earlier (Wit et al., 1989b). Height was measured 
every 3 months at the same time of the day using a 
Harpenden stadiometer. The mean of 4 measurements was 
used for analysis. Pubertal stages were scored according to 
the Tanner (1955) classification and compared with longi­
tudinal British references (Marshall & Tanner, 1969; 1970). 
Bone age determinations were performed by the same
©  1995 Blackwell Science Ltd, Clinical Endocrinology, 42, 4
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investigator using the method of Greulich and Pyle (1959) as 
well as the Tanner and Whitehouse method II (20 bones) 
(Tanner et al., 1983). Height was expressed as HSDS for age 
(Roede & Van Wieringen, 1985) and bone age. Height 
velocity was calculated over full years as SDS for bone age 
(Tanner et al., 1966), on which basis the dosage was or was 
not adapted. Height predictions were calculated by the 
method of Bayley and Pinneau (1952). Heights of father and 
mother were measured and target height was calculated as 
the sex-corrected mid parental height plus 3 cm, to account 
for the average secular trend.
We also investigated the predictive value, with respect to 
long-term response to rhGH therapy, of certain baseline 
parameters and of the height velocity increment during the 
first year of therapy. In this analysis HSDS for age, height 
velocity SDS for age, bone age delay, 24-hour integrated 
concentration of GH, maximum GH concentration during 
provocative test, plasma IGF concentration and height 
velocity increment during the first year of therapy were 
considered as independent variables while the difference 
between final height (ISS group 1) or predicted adult height 
after 6 or 7 years of rhGH therapy (ISS group 2) and the 
predicted adult height at start of therapy were used as 
measures of the response to rhGH treatment (dependent 
variable).
present 9 of the 21 treated patients are still on rhGH therapy 
(ISS group 1), all on a dose of 4 IU/m2 b.s. daily, whereas 12 
children have reached final height (ISS group 2). No clinical 
side-effects have been reported. All laboratory parameters 
remained normal during therapy.
Growth in patients still on rhGH therapy
In order to evaluate the efficacy of rhGH treatment in 
children with ISS who are still growing, we compared 
growth data of the ISS group 1 with those of a matched 
subsample of the untreated controls (matched ISS controls, 
n =  9) and with the GHD-group. The matching procedure, 
based on sex, age and HSDS for age at the start of the 
observation period, was performed because the HSDS for age 
at start was significantly higher in the complete cohort of ISS 
controls than in the ISS treatment group. At the start of the 
study there were no differences between the ISS group 1, the 
matched ISS controls and the GHD group regarding age and 
HSDS for age. Moreover, no differences between the ISS 
group 1 and the GHD group were present regarding bone age 
or HSDS for bone age (Table 1). A comparison of initial final 
height predictions with the Bayley-Pinneau method was not 
possible because in 5 patients from the GHD group the bone 
age at start was too young.
Statistical analysis
Results are expressed as mean ±  standard deviation (SD) 
unless indicated otherwise. Paired /-tests or repeated- 
measures analysis of variance and, in case of non-normality, 
Wilcoxon signed rank or Friedman statistic tests, were 
performed to assess differences within the groups. To test 
differences between the groups unpaired /-tests or analysis of 
variance and, in case of non-normality, Wilcoxon signed rank 
or Kruskal-Wallis tests were used. The correlations between 
various parameters were calculated by univariate linear 
regression analysis and expressed by Pearson’s correlation 
coefficient. Figures present mean ±  1 standard deviation.
Results
Over the first year of rhGH treatment, 16 out of the 21 
children in the ISS treatment group (76%) showed a height 
velocity increment of more than 2 cm/year on a dosage of 2 
IU/m2 daily. Four of them kept a height velocity above the 
mean for bone age during the complete treatment period, 
and continued on the initial dosage of 2 IU/m2 daily until 
they reached final height. The remaining 17 children were all 
labelled as non-responders at variable intervals (1-5 years) 
after the start of rhGH and the dosage was doubled. At
Height SDS fo r chronological age (Table 1, Fig. la ). In ISS 
group 1 the HSDS for age rose from —3 8 ± 0-7 at start of 
therapy to -2-5 ±  0-7 (P < 0 01) and -2-3 ± 0-9 (P < 0-01) 
after 4 and 6 years, respectively. In the matched ISS control
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Fig. 1 Height SDS for a, chronological age and b, bone age
in # ,  the rhGH treated ISS-group 1, in comparison to A* the 
untreated, matched ISS-control group and O, the rhGH treated 
GHD-group. Bone age according to Greulich and Pyle (1959).
©  1995 Blackwell Science Ltd, Clinical Endocrinology, 42, 4
Long-term GH therapy in idiopathic short stature 369
patients, HSDS for age did not change during 6 years of 
follow-up: at the ‘start’ HSDS for age was -3*2 ±  0-3, after
4 years it was -3-4 ±  0-6, and after 6 years -3-3 ±  0-6. The 
GHD group, for which data are available over a 4-year 
period of rhGH therapy, showed a significant increase in
After 4 and 6 years of follow-up the HSDS for age in ISS 
group 1 was significantly higher than in the matched ISS 
controls (P <  0-002). The HSDS for age of the GHD group 
after 4 years of treatment was also significantly higher than 
in the ISS controls (P < 0 002). Although the absolute 
values of HSDS for age after 4 years of rhGH treatment 
were not different between the ISS group 1 and the GHD 
patients, the increment of HSDS for age was significantly 
larger in the GHD group than in the rhGH treated ISS 
group 1 (2-0 ±  0-4 vì 1-3 ±  0-6, P <  0*02).
period. The mean final height SDS in all groups were similar 
and higher than the initial HSDS. However, final height was 
close to the initial Bayley-Pinneau predictions, while HSDS 
for BA overpredicted final height in the treatment and 
control group with a mean ±  SD of 1-1 ±0-8 and 1-8 ±  1-1 
SDS, respectively. The final height of ISS group 2 was 
8-7 ±  6-5 cm below the target height (P < 0-005), compared 
to 10-2 ±3-5 cm in the ISS bone age control group 
(P < 0-0001). A comparison within ISS group 2 of the 
patients who always received a dosage 2 IU/m2 b.s. daily 
and those in whom the dosage was doubled, revealed no 
significant differences with respect to final height, final 
height minus target height, final height minus predicted 
adult height at start of therapy, HSDS for age at stop and 
HSDS for adults (data not shown). A similar comparison 
between boys and girls also revealed no differences.
Bone age development. During the first 4 years of rhGH 
therapy the mean bone age advancement according to 
Greulich and Pyle in ISS group 1 was comparable to that in 
the GHD group: 5-4 ±  0*8 years and 5-0 ±  0-8 years, 
respectively. In both groups the increment in bone age 
exceeded the increment in age during this period (P < 0*05). 
In ISS group 1 the mean bone age increment over 6 years of 
treatment was 7-0 ±  1*3 years.
Height SDS fo r bone age (Fig. lb ) .  In both ISS group 1 and 
the GHD group, HSDS for bone age showed little change. 
HSDS for bone age after 4 years of rhGH did not differ 
between the groups, and its change over 4 years was 
-0*5 ±  1*0 in the ISS group and +0-2 dh 1-0 in the GHD 
group (NS).
Predicted adult height (Table 1). In ISS group 1 predicted 
adult height SDS increased from — 2-4 dt 1-7 to -1-8 ±  1-6 
after 6 years of rhGH therapy (NS). The increment in 
predicted adult height SDS was 0-6 ±  1-1 (NS). As explained 
earlier, no data on predicted adult height changes could be 
calculated for the GHD group.
Data on final height
In order to study final height results of rhGH therapy in ISS 
we compared the data of the treated ISS subjects who have 
reached final height (ISS group 2) with those of a second 
subsample of the retrospectively selected cohort of 
untreated children with ISS in whom reassessment of bone
performed 9). The
results are shown in Table 2. ISS bone age controls did not 
differ from the complete untreated control group regarding 
age, height, and HSDS for age at start of the observation
Pubertal development
All 21 children from both ISS groups entered puberty during 
the treatment period, and 18 had reached at least pubertal 
stage 4 at the moment of analysis. The chronological age at 
onset of puberty, which is defined as Tanner stage G2/B2, 
was 13*7 ±  1*2 years in boys and 11-7 ±  0-8 years in girls, 
whereas the mean British references are 11-6 ±  1-1 years and 
11 *2 ±1-1 years, respectively (Marshall & Tanner, 1970; 
1969). The bone age according to Greulich and Pyle at start 
of puberty was 11-5 ±  0-9 in boys and 10*3 ±  0-3 in girls. At
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Fig. 2 Progression through puberty of a, boys; b, girls from 
both ISS-groups in comparison with — , British references 
(Marshall & Tanner, 1969; Marshall & Tanner, 1970).
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Table 3 Correlation coefficients between clinical and biochemical 
parameters at start of GH therapy and final height or predicted 
adult height after 6 or 7 years therapy minus initial prediction.
r P
ICGH (n =  14) -0 6 1 002
Bone age delay at start (n — 20) *—0*52 002
Max. GH in prov. test (n =  15) -0-58 002
IGF-I (« =  15) 0-21 0-45
Height velocity increment 1st year GH (n =  20) 0-03 0-90
HSDS for age at start (n = 20) 0-02 0-92
Height velocity SDS at start (n =  20) 0-02 0-93
ICGH, Integrated concentration of serum GH during 24-hour 
profile.
that moment, the median bone age delay in boys was 2-4 
(range 0-2-3-9, mean ±  SD =  2'1 ±  1-1) years, and 1’6 
(range 0*6-1-9, mean ±  SD =  1-5 ±  0-5) years in girls. The 
difference between the bone age delay in boys and girls was 
not significant. The mean duration of puberty, defined as the 
interval between Tanner stage G2/B2 and G4/B4, was 
1-4 ±  0-6 years in boys (n — 11) and 2-5 ±  0-6 years in girls 
(n =  7), in contrast to 19 years in the male
(P2-5 P97-5 0-7—3-8) and 2-0 ±0-9 years in the female
reference population (Marshall & Tanner, 1970; 1969) (Fig. 
2). Our data suggest that GH shortens the duration of 
puberty in boys, but the lack of reliable control data hinders 
statistical confirmation.
Factors predicting the outcome of rhGH therapy
Table 3 shows the results of univariate linear regression 
analysis between some initial clinical and biochemical 
parameters and the final response to rhGH therapy, defined 
as the difference between final height (ISS group 2) or the 
predicted adult height after 6 or 7 years of rhGH treatment 
(ISS group 1) and the initial predicted adult height. The 
response to rhGH treatment was significantly negatively
related to the bone age delay at start of therapy (r 0-52;
P ~  0-02), to the integrated concentration of GH
(r 0-61; P — 0 02), and to the maximum GH peak
during a provocation test (r 0'58; P < 0 02). A stepwise
multiple regression analysis showed that bone age delay at 
start of therapy and integrated concentration of GH were 
the parameters with the highest predictive value, and 
resulted in the following equation:
height gain -4-48(SE 1-00) x BA delay at start 
-0-95(SEO*30) x ICGH 
+ 20-65ÍSE3-17)
No relation was found with the initial plasma concentra­
tion of IGF-I, HSDS for age, height velocity SDS for age, or 
with the height velocity increment during the first year of 
treatment. Bone age delay was positively correlated with the 
ratio of bone age advance over age during 4 years of GH 
therapy (r — 0-50; P =  0-02), but not with integrated 
concentration of GH (r =  0-20; NS). Similar correlations 
were found if only the children in whom final heights were 
available were included.
Discussion
*
i
i  <
The present study, as well as previous papers ’(Hopwood et 
al., 1993; Hindmarsh & Brook, 1987; Moore et al., 1992; Wit 
et al., 1989a,b; 1990), demonstrates that GH therapy in a 
daily dose of 1-2 times the substitution dose leads to 
increased growth velocity over several years in children with 
ISS, resulting in a HSDS increment of 1.5, provided that the 
dosage is adapted to the individual sensitivity. The average 
response, however, was less than the response of children 
with ‘classic’ isolated GHD to a substitution dosage 
(approximately 2 SD over 4 years) and the. mean height 
remained below the 3rd percentile.
The response to GH therapy in ISS was, besides being 
lower than in GH deficient children, also heterogeneous. In 
fact, 75% of our patients showed a significant acceleration 
in height velocity during the first year of treatment with a 
regular substitution dose of rhGH, whereas in the others a 
higher dose was needed to obtain a significant increment. In 
the following years, the GH dosage had to be doubled in 
most of our patients in order to maintain the height velocity 
above the mean for bone age. Only in 4 patients , of whom 3 
had a low integrated concentration of GH, was the regular 
GH dosage sufficient to maintain growth velocity above the 
average for bone age until final height.
These results, in combination with the wide variation in 
endogenous GH secretion in our patients (Wit et al. 1989b), 
are in line with the earlier observations that children with 
ISS differ in terms of GH secretion and GH sensitivity: some 
children can be classified as suffering ‘GH neurosecretory 
dysfunction’ (Bercu et al., 1986; Spiliotis et al., 1984), while 
in others a relative insensitivity for GH is suggested by 
relatively low levels of GH-binding protein (Fontoura et al., 
1992), which may reflect the cellular GH receptor status 
(Daughaday et a l,  1987) in such patients.
In contrast to the increase in HSDS for age, GH therapy 
did not increase HSDS for bone age or predicted adult 
height in children with ISS and GHD, due to the accelerated 
bone maturation, a finding also reported by other 
investigators (Hopwood et al., 1993; Tanaka et al., 1993). 
This may be partly caused by the shorter duration of
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puberty as observed in the GH treated boys, which is in line 
with observations in GH deficient children (Darendeliler et 
al., 1990). However, the fact that this acceleration of bone 
maturation also occurs in girls with Turner’s syndrome 
treated with higher than replacement doses of rhGH (Massa 
et al., 1993; Rongen-Westerlaken et al., 1992) suggests that
children with a low growth velocity and a low 24-hour 
integrated concentration of GH. It is also compatible with 
the general assumption that the response to GH therapy is 
better in GH deficiency than in other short children.
A surprising finding was that the bone age delay, which 
would be suspected to correlate positively with the degree of
it is at least in part caused by a direct effect of GH or insulin­
like growth factors on the developing growth cartilage, and 
not only by sex steroids. Studies evaluating the effect of 
delaying puberty in ISS subjects during rhGH treatment 
with GnRH-agonists, are needed to answer the question 
whether pubertal development substantially interferes with 
the growth promoting effect of GH.
So far, limited information is available on final height of
GH insufficiency and therefore with the gain in final height, 
was negatively related to the final outcome. This is probably 
caused by a relatively large bone age advance in children 
with a large initial bone age delay, thereby limiting the effect 
on final height. Height velocity before or during the first 
year of treatment had no predictive value, suggesting that 
short-term results do not reflect long-term results of GH 
treatment.
children with ISS treated with GH. Our results show that, 
although final height SDS for age is about 1 SD higher than
In conclusion, GH treatment induces a significant 
increase of height standard deviation score for chronologi-
the initial HSDS, it is still situated 2-5 SD below the 
population’s mean and 9 cm below target height, similarly to
cal age during treatment in idiopathic short stature, but 
average final height does not improve due to advanced bone
untreated controls. These findings suggest that the average maturation. In children with classic isolated GH deficiency
result of 6 or more years daily rhGH injections is about 0-4 the growth response is better, but also associated with an
SD, which is 2-4 cm. These results are not necessarily in advancement of bone age. There is a large interindividual
conflict with the results of a study (Zadik et al., 1992b) variation in the response to GH treatment and a 24-hour
showing a positive effect of GH on final height in 17 integrated concentration GH can to some extent discrimi-
peripubertal boys with ISS and a subnormal integrated nate between responders and non-responders, while a large
concentration of GH, as in our study also children with a bone age delay is a negative predictor. Assuming that a taller
low integrated concentration of GH did better than the final height is the main response parameter, rather than a
others. Our data are in line with those of a recent temporary growth acceleration during childhood and
collaborative study on children with variable endogenous adolescence, GH treatment is not indicated in short
GH secretion (Guyda, 1994). children without clear evidence for GH deficiency. Further
In the children with ISS who did not undergo GH refinement of the diagnosis of GH secretion and GH
treatment, final height was very close to the prediction at the responsiveness is needed for a better selection of patients
start of the observation period, but significantly below the eligible for GH therapy.
target height and below the initial HSDS for bone age, 
which is consistent with earlier reports (Brâmswig et al.,
1990; Crowne et a i, 1990). This means that for a group Acknowledgements
analysis predicted adult height can be used for evaluating 
the effect of GH therapy, although on an individual basis 
there is still a substantial error.
This work was supported by a grant from Kabi Pharmacia 
Peptide Hormones.
We have previously reported that indicators of endogen-
ous GH secretion did not predict the first year response to 
GH treatment (Wit et a l, 1989b). In contrast to this finding, 
our present analysis shows that the integrated concentration 
of GH and the GH response to secretagogues are 
significantly negatively correlated to the long-term effect 
of rhGH treatment: the lower the integrated concentration 
of GH and stimulated GH secretion, the better the effect of 
GH treatment on final height. This is in line with the 
observations of Zadik et a l (1992a) reporting that the 
benefit from GH therapy in children with a normal growth 
velocity and a normal integrated concentration of GH is 
poor, whereas marked growth acceleration was noted in
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